Bio-Rad Laboratories Inc (NYSE: BIO) on Friday, plunged -9.53% from the previous trading day, before settling in for the closing price of $306.36. Within the past 52 weeks, BIO’s price has moved between $262.12 and $387.99.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 3.10% over the past five years. The company achieved an average annual earnings per share of -4.10%. With a float of $19.16 million, this company’s outstanding shares have now reached $22.94 million.
Let’s look at the performance matrix of the company that is accounted for 7700 employees. In terms of profitability, gross margin is 53.77%, operating margin of 10.72%, and the pretax margin is -91.27%.
Bio-Rad Laboratories Inc (BIO) Insider and Institutional Ownership
Observing investor behavior towards Medical Devices industry stocks is more important than anything else. The insider ownership of Bio-Rad Laboratories Inc is 31.57%, while institutional ownership is 67.98%. The most recent insider transaction that took place on Nov 06 ’24, was worth 1,120,934. Before that another transaction happened on Sep 12 ’24, when Company’s Officer proposed sale 1,600 for $321.57, making the entire transaction worth $514,505.
Bio-Rad Laboratories Inc (BIO) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of 2.47 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -4.10% per share during the next fiscal year.
Bio-Rad Laboratories Inc (NYSE: BIO) Trading Performance Indicators
Bio-Rad Laboratories Inc (BIO) is currently performing well based on its current performance indicators. A quick ratio of 4.85 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.09. Likewise, its price to free cash flow for the trailing twelve months is 27.46.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -65.04, a number that is poised to hit 1.85 in the next quarter and is forecasted to reach 11.66 in one year’s time.
Technical Analysis of Bio-Rad Laboratories Inc (BIO)
Bio-Rad Laboratories Inc (NYSE: BIO) saw its 5-day average volume 0.42 million, a positive change from its year-to-date volume of 0.2 million. As of the previous 9 days, the stock’s Stochastic %D was 8.16%. Additionally, its Average True Range was 12.79.
During the past 100 days, Bio-Rad Laboratories Inc’s (BIO) raw stochastic average was set at 3.05%, which indicates a significant decrease from 3.49% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 45.30% in the past 14 days, which was higher than the 39.55% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $338.15, while its 200-day Moving Average is $321.28. Nevertheless, the first resistance level for the watch stands at $294.87 in the near term. At $312.58, the stock is likely to face the second major resistance level. The third major resistance level sits at $323.18. If the price goes on to break the first support level at $266.56, it is likely to go to the next support level at $255.96. The third support level lies at $238.25 if the price breaches the second support level.
Bio-Rad Laboratories Inc (NYSE: BIO) Key Stats
Market capitalization of the company is 7.94 billion based on 27,997K outstanding shares. Right now, sales total 2,671 M and income totals -637,320 K. The company made 649,730 K in profit during its latest quarter, and 653,170 K in sales during its previous quarter.
